BPC-157 & TB-500 Peptide Blend
BPC-157 Peptide, also referred to as Pentadecapeptide BPC-157 or Body Protection Compound 157, is a fully synthetic peptide studied for roles in cellular processes and in experimental models of injury healing. Research suggests it engages cell-signaling pathways tied to rejuvenation and recovery. Early studies indicate potential to promote angiogenesis and to modulate inflammation. Additional experimental findings propose protective and regenerative effects across various cells and tissues, suggesting possible support for joint, tendon, muscle, and nerve tissues in research settings.
TB-500 Peptide, also known as synthetic thymosin beta-4 (TB-4), has been explored by researchers for potential assistance in recovery after injury, including brain and neurological models. Other investigations examine wound-healing and hair-growth effects. As a laboratory-made analog of the naturally occurring thymosin beta-4 encoded by the TMSB4X gene, TB-500 appears to influence cell migration, differentiation, and tissue repair through multiple signaling routes. Studies also suggest pro-angiogenic activity alongside broader cellular and tissue renewal.
Both BPC-157 and TB-500 are synthetic polypeptides, with TB-500 composed of 43 amino acids and BPC-157 composed of 15 amino acids.
Overview
Drawing on thymosin β-4 (TB-500) literature, TB-500 has been proposed to influence cellular motility by engaging the actin network—regulating the actin cytoskeleton, sequestering G-actin, and elevating actin-related proteins. It contains the LKKTET motif (residues 17–23), which has been linked to actin binding and enhanced cell movement, and these actions have been associated with favorable effects in wound-healing models. TB-500 has also been reported to increase microRNA-146a (miR-146a), a repressor of inflammatory signaling involving IRAK1 and TRAF6; when miR-146a is blocked, the effect is reversed, suggesting a potential anti-inflammatory route that could support tissue repair.
BPC-157 has been described across studies as acting through several processes, including nitric-oxide signaling, regulation of cells involved in tissue restoration, growth-factor activity, and inflammatory responses. It has been hypothesized to safeguard the endothelium via NO-related pathways and to encourage angiogenic behavior by supporting new vessel formation. Some reports note increased expression of the early growth response gene Egr-1—implicated in cytokine and growth-factor production and in the early assembly of extracellular matrix such as collagen. Work has also discussed interactions with the NGFI-A (Egr-1) binding protein-2 complex that may exert inhibitory effects on certain targets. Together, these mechanisms are proposed to facilitate faster collagen deposition and, in turn, quicker wound closure in experimental models.
Because TB-500 and BPC-157 are each associated with overlapping yet complementary actions, some researchers suggest that, when used together, the combined potential could exceed what is observed with either peptide alone, possibly producing stronger or faster effects in like-for-like models.
Chemical Makeup
Molecular Formula:
- BPC-157: C62H98N16O22
- TB-500: C212H350N56O78S
Molecular Weight:
- BPC-157: 1419.7 g/mol (Expected = Observed 1419.7)
- TB-500: 4963 g/mol
Other Known Titles
BPC-157: Body Protection Compound-157
TB-500: Thymosin Beta-4
Research and Clinical Studies
Research and Clinical Studies
There are currently no published studies in which TB-500 and BPC-157 were evaluated together in the same experiment or within the same test model. The summaries below describe findings reported when each peptide was studied separately.
BPC-157 & TB-500 Blend and Tissue Repair
In a 1999 investigation using experimentally wounded mice, half the animals received saline while the others received TB-500. By day four, the TB-500 group showed an ~41% increase in re-epithelialization (new epithelial coverage of the wound). By day seven, TB-500–treated wounds had contracted at least 11% more than saline controls. The authors stated that thymosin β-4 (TB-500) appeared to be a potent wound-healing factor with multiple activities.
In a 2006 randomized, double-blind clinical trial of 72 participants with pressure ulcers, subjects received either placebo for up to 84 days or daily TB-500 at various concentrations over the same period. At day 84, the TB-500 groups exhibited evidence of wound-healing activity.
In a BPC-157 study employing three mouse wound models (acute and chronic), animals were assigned to placebo or BPC-157. Histological analysis showed that BPC-157 groups developed a markedly greater amount of collagen and a higher density of blood vessels than placebo groups.
BPC-157 & TB-500 Blend and Ligaments
In a surgical model where the medial collateral ligament (MCL) of mice was transected, all animals received a fibrin sealant and a subset additionally received thymosin β-4 (TB-500). Four weeks later, tissues from the TB-500 group showed more evenly organized, regularly spaced collagen fibers that were wider than in controls. The mechanical properties of the healing femur–MCL–tibia complexes also appeared improved relative to the control group.
Separate research suggests that BPC-157 may aid connective-tissue recovery by promoting tendon explant growth and improving tolerance to oxidative stress. Findings included greater F-actin formation (via FITC-phalloidin staining), enhanced migration of tendon fibroblasts in a transwell assay, and faster fibroblast spreading across culture plates. The FAK–paxillin pathway was implicated: phosphorylation of both FAK and paxillin increased with BPC-157, while total protein levels remained unchanged.
BPC-157 & TB-500 Blend and Muscle
A study in mice with corticosteroid-aggravated injury to the gastrocnemius muscle divided subjects into placebo or daily BPC-157 for up to 14 days. The BPC-157 group achieved complete restoration of muscle structure and function, whereas the placebo group showed no meaningful improvement.
Additional work indicates that TB-500 may influence muscle regeneration, particularly in cardiac tissue. Reports describe improved tolerance to low-oxygen conditions and promotion of angiogenesis, with indications that cardiac fibroblasts can shift toward cardiomyocyte-like cells. In coronary-ligation mouse models, TB-500 has been associated with higher integrin-linked kinase (ILK) and protein kinase B (Akt) activity, potentially improving early cardiomyocyte survival and overall heart performance. TB-500 has also been observed to support movement of myocardial and endothelial cells in the fetal heart, with this capacity persisting in mature cardiomyocytes.
BPC-157 & TB-500 peptide blend is offered for research and laboratory purposes only. Please review and follow the Terms and Conditions before ordering.
References:
- Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L. B., Pavlov, K. H., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Zizek, H., Durasin, T., Dobric, I., Staresinic, M., Strbe, S., Knezevic, M., Sola, M., Kokot, A., Sever, M., … Sikiric, P. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533
- Maar, K., Hetenyi, R., Maar, S., Faskerti, G., Hanna, D., Lippai, B., Takatsy, A., & Bock-Marquette, I. (2021). Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies. Cells, 10(6), 1343. https://doi.org/10.3390/cells10061343
- National Center for Biotechnology Information. “PubChem Compound Summary for CID 132558700, CID 132558700” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/132558700
- National Center for Biotechnology Information. “PubChem Compound Summary for CID 9941957” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Bpc-157
- Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039. PMID: 18480812. https://pubmed.ncbi.nlm.nih.gov/18480812/
- Santra, M., Zhang, Z. G., Yang, J., Santra, S., Santra, S., Chopp, M., & Morris, D. C. (2014). Thymosin β4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway. The Journal of biological chemistry, 289(28), 19508–19518. https://doi.org/10.1074/jbc.M113.529966
- Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC-157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#r1
- Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/
- Katherine M. Malinda et.al, Thymosin β4 Accelerates Wound Healing, Journal of Investigative Dermatology, Volume 113, Issue 3, 1999, Pages 364-368, ISSN 0022-202X, https://www.sciencedirect.com/science/article/pii/S0022202X15405950
- Study of Thymosin Beta 4 in Patients With Pressure Ulcers. https://www.clinicaltrials.gov/ct2/show/NCT00382174
- S Seiwerth, et al. “BPC-157’s effect on healing.” Journal of physiology, Paris vol. 91,3-5 (1997): 173-8. doi:10.1016/s0928-4257(97)89480-6. https://pubmed.ncbi.nlm.nih.gov/9403790/
- Xu B, Yang M, Li Z, Zhang Y, Jiang Z, Guan S, Jiang D. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013 Jun 10;184:1-5. doi: 10.1016/j.regpep.2013.03.026. https://pubmed.ncbi.nlm.nih.gov/23523891/
- Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC-157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676. https://pubmed.ncbi.nlm.nih.gov/20190676/
- Srivastava, D., Ieda, M., Fu, J., & Qian, L. (2012). Cardiac repair with thymosin β4 and cardiac reprogramming factors. Annals of the New York Academy of Sciences, 1270, 66–72. https://doi.org/10.1111/j.1749-6632.2012.06696.x
- Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. https://doi.org/10.1038/nature03000
Dr. Marinov
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
